Drugs / CC-3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05999396 | Jan 2024 → Oct 2026 expected | breast carcinoma, colorectal cancer, penile carcinoma, sarcoma | German Cancer Research Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CC-3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05999396 ↗ |
| Action | Deplete | “CC-3 also induced potent tumor cell lysis and T cell proliferation across all patient-derived tumor samples” PMID 42094867 ↗ May 2026 |
| Target | CD276 | “CC-3 binds to CD276 on cancer cells as well as to tumor vessels of CRC” NCT05999396 ↗ |